Understanding how the FDA drug approval process influences biotech stock prices isn’t just useful—it’s essential for anyone holding or considering positions in pharmaceutical companies. The relationship between regulatory milestones and stock valuation follows patterns that experienced investors have learned to recognize, though these patterns are far more complex than simple cause-and-effect. I’ve watched biotech stocks swing 300% in a single trading day based on FDA decisions, and I’ve seen companies lose half their value in an hour when a clinical trial failed. What I’m about to walk you through represents the culmination of years observing how the market prices in regulatory risk at each stage of the drug development pipeline.
Before a company even files an Investigational New Drug (IND) application, it exists in what Wall Street calls the “preclinical” stage—and this is where some of the most asymmetric risk-reward opportunities exist. During preclinical development, a company is typically valued based almost entirely on its scientific hypothesis, the credentials of its management team, and the size of its addressable market. There’s no human data to validate the approach, which means institutional investors are largely making educated guesses about probability of success.
Companies like Axsome Therapeutics traded in extremely low volumes during their preclinical years, with market caps hovering below $50 million despite having novel mechanisms for treating depression and neurodegenerative disorders. The stock didn’t really begin its transformation until they entered human trials. What matters at this stage isn’t the stock price itself—it’s the cash burn rate and the company’s ability to fund operations until they reach more binary catalysts. A common mistake newer investors make is trying to “value” a preclinical biotech using traditional metrics like P/E ratios. That approach misses the point entirely. These companies are options on future clinical data, and the price you pay now is the premium you’re paying for that option.
The practical takeaway: if you’re evaluating preclinical companies, focus on cash runway (how many quarters can they operate without raising money?), the strength of their intellectual property (composition of matter patents versus method-of-use patents), and whether management has prior experience getting drugs through the FDA pipeline. Don’t expect the stock to move much until they file that IND.
When a company files an IND with the FDA, they’re essentially asking for permission to begin human clinical trials. This is traditionally the first major stock-moving event in a drug’s development lifecycle—and it’s one where I frequently see retail investors over-react.
The IND filing itself is typically a non-event from a stock movement perspective because these filings are almost always successful. The FDA has 30 days to review an IND, and they allow the vast majority to proceed to clinical trials. However, the announcement of an IND filing can create modest volatility, particularly in companies with limited analyst coverage where the market may not have been pricing in this milestone.
A more significant dynamic occurs when a company receives an IND hold—essentially a regulatory pause while the FDA requests additional information. This happened to CytoDyn in 2020 regarding their leronlimab program, and the stock dropped sharply on the news despite the company ultimately resolving the hold. The lesson here is that IND holds are relatively rare but genuinely material, while routine IND clearances are largely priced in or ignored entirely.
After the IND clears, companies usually announce the initiation of Phase 1 trials, which becomes the next countdown event on the calendar. Between IND clearance and Phase 1 readout, expect trading volume to gradually increase as more sophisticated investors build positions ahead of the first human data.
Phase 1 trials represent the first real test of whether a drug is safe in humans. These studies typically involve 20-80 healthy volunteers and focus primarily on safety and tolerability, though they also gather preliminary efficacy data. From an investment perspective, Phase 1 readouts are where you first encounter the dramatic biotech stock movements that make this sector notorious.
The key thing to understand about Phase 1 data is that the market typically prices in a binary outcome. If the data shows the drug is safe and demonstrates any hint of efficacy, stocks frequently double or triple. If the data reveals safety concerns or complete lack of efficacy, stocks can drop 50% or more in after-hours trading.
Consider what happened with Axsome Therapeutics when they released Phase 1 data for their treatment for major depressive disorder. The stock moved significantly on relatively limited data because the market was pricing in the conceptual validation—that the mechanism actually worked in humans. Similarly, when Moderna announced early Phase 1 data for their COVID-19 vaccine in May 2020, the stock surged over 20% in a single day despite the data involving only eight patients. That reaction might seem excessive, but it reflects how the market weights validation of a novel mRNA platform.
What many investors fail to appreciate is that Phase 1 movements often set the ceiling for Phase 2. A stock that triples on Phase 1 data will need extraordinary Phase 2 results to continue rising at the same rate. The probability of success from Phase 1 to Phase 2 approval is roughly 70% for oncology drugs and around 60% for non-oncology drugs, according to industry data from PhRMA. Those aren’t bad odds, but they mean the market is often too optimistic about early-stage programs.
Phase 2 is where the rubber meets the road. These trials involve hundreds of patients with the target disease and are designed to demonstrate that the drug actually works. Phase 1 proves a drug won’t kill you; Phase 2 proves it might actually help you. This distinction matters enormously for stock valuation.
Phase 2 readouts typically generate the largest single-day moves in the biotech sector because they represent the first robust dataset on clinical efficacy. When a Phase 2 trial succeeds, companies often see stock appreciation of 100% to 500%. When they fail, the decline is equally brutal—frequently 70% or more in a single session.
The biotech world is littered with examples. When Biohaven Pharmaceutical’s rimegepant demonstrated positive Phase 2 results for acute migraine treatment, the stock went from around $15 to over $50 in the weeks following the readout. The subsequent Phase 3 success and eventual FDA approval validated that move, though the stock experienced significant volatility along the way.
Here’s where I’ll offer an opinion that conflicts with conventional wisdom: I believe Phase 2 is actually overweighed by the market relative to Phase 3. Everyone watches Phase 2 like a hawk, but Phase 3 failures still happen roughly 30% of the time even after successful Phase 2 trials. The reasons are varied. Phase 3 trials are larger and longer, sometimes revealing safety issues that didn’t appear in smaller studies, or they may use different endpoints or patient populations. Investors who pile into a stock after Phase 2 success are often taking on more risk than they realize.
The practical advice: use Phase 2 success as a signal to begin serious due diligence, not as a reason to buy immediately. Wait for the market to digest the data, look at how management discusses the results on earnings calls, and watch for insider buying or selling in the weeks following the announcement.
Phase 3 trials are the definitive test—the large-scale, randomized, controlled studies that the FDA requires to demonstrate a drug’s benefits outweigh its risks. These trials involve hundreds to thousands of patients and can cost hundreds of millions of dollars to conduct. From a stock perspective, Phase 3 is where the binary nature of biotech investing reaches its peak.
Phase 3 readouts are the most consequential events in a drug’s development timeline, and the market treats them accordingly. The stock movements can be extreme in both directions, but there’s a nuance here that many investors miss: the market often begins pricing in Phase 3 outcomes before the data is released.
This phenomenon, sometimes called “anticipatory trading,” means that stocks frequently rise heading into a positive Phase 3 readout and fall heading into a negative one. The problem is that this makes it nearly impossible to profit from the actual announcement unless you have material non-public information—which would be illegal to trade on. What ends up happening is that a successful Phase 3 may cause the stock to actually drop on the news if the data was already priced in, while an unsuccessful trial causes a much smaller decline than would have occurred if the stock hadn’t already been depressed.
A real-world example: when Biogen’s aducanumab was evaluated in Phase 3 trials, the stock experienced enormous volatility in the months leading up to the data. The ultimate readout was mixed—the trial met one primary endpoint but not another—and the stock dropped sharply despite the data being roughly in line with what sophisticated investors had expected. The subsequent FDA approval decision in June 2021 created another dramatic move, with the stock swinging 60% in a single week.
My honest assessment: Phase 3 is where institutional money really matters. Retail investors are at a structural disadvantage because the smart money has already positioned for the outcome by the time the data drops. The best strategy is to avoid trying to time the binary event itself and instead focus on position sizing—never risk more than you’re willing to lose entirely on a single Phase 3 bet.
Once Phase 3 trials are complete, a company submits a New Drug Application (NDA) or a Marketing Authorization Application (MAA) in Europe. This submission triggers a formal review period—typically 10 months in the US for standard review, with priority review designation cutting that to six months.
Here’s what surprises most people: stock movements during the review period are often more predictable than during the trial itself. Once an NDA is accepted for filing, the probability of approval becomes more quantifiable. The FDA publishes approval rates by therapeutic area, and these historical rates inform how the market prices risk during the review period.
Oncology drugs have FDA approval rates around 70% following NDA submission, while drugs for rare diseases or with breakthrough therapy designation can have even higher approval rates. Cardiovascular and metabolic drugs tend to have lower approval rates, around 50-60%.
During the review period, stocks typically trade in a range unless something material happens—such as an FDA advisory committee meeting announcement, which I’ll discuss separately. Companies also frequently release additional analyses or post-hoc data from their clinical trials during this period, which can move the stock as investors reassess the probability of approval.
One underappreciated factor: the FDA’s complete response letter (CRL), which indicates the application cannot be approved in its current form, can absolutely tank a stock even if the issues raised are fixable. The market hates uncertainty, and a CRL introduces substantial uncertainty about timing and ultimate approval. Spero Therapeutics received a CRL for their urinary tract infection drug in 2022, and the stock dropped 70% despite the company working to address the FDA’s concerns.
Before the FDA makes its final approval decision for many drugs, it convenes an Advisory Committee meeting where external experts evaluate the application’s data and vote on whether they recommend approval. These meetings are not binding, but the FDA follows their recommendations approximately 80% of the time.
Advisory Committee meetings generate extraordinary volatility because they’re public, they feature debate among experts, and they often reveal concerns that weren’t apparent from the company’s press releases. The voting outcome—particularly the margin of victory—significantly influences how the market prices approval probability.
The Amgen advisory committee for their KRAS inhibitor sotorasib in 2021 exemplified this dynamic. The stock traded actively in the weeks leading up to the meeting, with various analysts publicly debating the likelihood of a positive vote. When the committee ultimately voted favorably (though with some reservations about the trial design), the stock moved modestly on the news because the outcome had been broadly anticipated.
In contrast, the advisory committee for Biogen’s aducanumab was contentious and split nearly evenly, which created enormous uncertainty about what the FDA would ultimately decide. The stock was volatile for weeks both before and after the meeting as traders tried to handicap the ultimate regulatory outcome.
The practical insight: Advisory Committee meetings are excellent opportunities for experienced investors to profit from volatility if they’ve done the homework to understand what the experts are likely to focus on. Read the briefing documents the FDA publishes ahead of the meeting. They’re often more critical than the company’s submission. Look for red flags in the FDA’s questions to staff.
The actual FDA approval decision is the ultimate binary event in biotech investing. When the FDA approves a new drug, the stock can surge dramatically—or it can sell off if the approval was already priced in or if the label is more restrictive than expected.
This is where I’ll push back against a common piece of advice I see in the biotech investing space: the idea that “buy the rumor, sell the news” always applies to FDA approvals. That saying has some truth to it, but it’s far from universal. Some of the most profitable biotech trades of the past decade have been simply holding through FDA approval. The key is understanding whether the market has fully priced in the approval probability.
When Moderna received FDA approval for their COVID-19 vaccine in December 2020, the stock actually dropped on the news despite the momentous nature of the event. Why? Because the market had been pricing in approval for months, and the company had already generated enormous revenue from emergency use authorization. The approval itself was priced in; what mattered was the company’s ability to exceed those already-elevated expectations going forward.
Conversely, when Vertex Pharmaceuticals received FDA approval for their cystic fibrosis drug Orkambi in 2015, the stock rallied significantly because the approval came with a broader label than some analysts had expected, which expanded the commercial opportunity.
The lesson: always read the FDA approval letter and the drug label carefully. The approved indication, the patient population, any REMS (Risk Evaluation and Mitigation Strategy) requirements, and the competitive landscape all matter enormously for the stock’s post-approval trajectory.
After FDA approval, a biotech company’s stock transitions from being primarily a function of clinical trial outcomes to being driven by commercial fundamentals—sales performance, market share, reimbursement dynamics, and competitive developments. This is a critical transition point that many investors fail to appreciate.
During the commercialization phase, companies that successfully launch their drugs can continue appreciating if sales exceed expectations, while companies that fail to generate adequate revenue often see their stocks decline even after approval. Gilead Sciences experienced this dynamic with their hepatitis C drugs. After the initial approval rally, the stock actually declined significantly as the market digested the reality that the cure was so effective it would eventually exhaust the patient pool.
The volatility doesn’t disappear after approval. Phase 4 studies can reveal safety issues that weren’t apparent in earlier trials (as happened with Vioxx, which was withdrawn from the market years after approval), and competitive developments can dramatically reshape the commercial outlook. When Eli Lilly and Novo Nordisk introduced GLP-1 agonists for weight loss, the impact on other metabolic disease companies was substantial and is still unfolding.
For investors holding stocks through the approval milestone, the key question to ask is: does the current valuation assume perfection? If the stock is priced as if every future drug in the pipeline will succeed, you’re likely paying too much. The best biotech investors constantly recalibrate their expectations based on what’s actually happening in the commercial rollout.
Understanding the approval stages is necessary but not sufficient for predicting biotech stock movements. Several variables moderate how any given regulatory event affects valuation, and these factors often matter more than the headline outcome.
First, analyst coverage and institutional ownership determine how efficiently information gets priced into a stock. Thinly-covered biotechs can experience much larger moves because the bid-ask spread is wider and there are fewer sophisticated participants to arbitrage away mispricings. Second, the size of the addressable market matters. A successful Phase 2 trial for a rare disease affecting 5,000 patients will generate less interest than a successful trial for a cholesterol drug affecting millions.
Third, the competitive landscape is critical. A successful trial for a drug that will compete against established therapies in a crowded space generates less enthusiasm than a first-in-class mechanism addressing an unmet need. Fourth, trial design matters. FDA regulatory science has become increasingly sophisticated, and trials with adaptive designs or innovative endpoints may receive more scrutiny.
Finally, market conditions themselves influence biotech volatility. During bull markets, investors are more willing to take binary risk on clinical trial outcomes, which amplifies both upward and downward movements. During bear markets or periods of risk aversion, the same binary events can generate even more extreme moves as traders de-leverage.
I’ve been straightforward about the mechanics of FDA-related stock movements, but I want to acknowledge where my advice has genuine limitations. The biggest one is this: no amount of understanding the approval process will make you consistently profitable at trading around binary events. The information asymmetry between institutional investors and retail participants is real, and by the time a Phase 3 readout is public, the smart money has already positioned.
Another limitation: even fundamentally sound analysis can be overwhelmed by broader market sentiment. A biotech with perfect Phase 3 data can still drop 20% if the broader market is cratering that day. These correlation effects make it nearly impossible to isolate pure FDA-related movements from general market noise.
The final caveat: regulatory outcomes are inherently unpredictable. The FDA has rejected drugs with strong clinical data due to manufacturing concerns, approval delays, and political pressure. Trying to predict these outcomes with precision is fool’s errand. The best strategy is position sizing—never allocate more capital to any single binary event than you can afford to lose entirely.
What separates successful biotech investors from those who get burned is not superior predictive ability; it’s discipline around position sizing, realistic expectations about probabilities, and the emotional fortitude to hold through volatility when the underlying thesis hasn’t changed. The FDA approval stages will continue driving biotech stock movements as long as the pharmaceutical industry exists—but the market will continue being dominated by participants who underestimate the complexity and overestimate their ability to predict outcomes. Don’t be one of them.
The nuclear energy sector is finally moving again, and the investment world is noticing. After…
The relationship between government energy policy and renewable stock returns isn't subtle — it's the…
The renewable energy transition has a problem that Wall Street is only starting to factor…
The green hydrogen sector is entering a period where picking winners actually matters. Between now…
The utility sector is changing, and understanding the difference between integrated utility stocks and pure-play…
The offshore wind industry is no longer a speculative bet on future technology. It is…